Literature DB >> 9332816

The sensitive detection and quantitation of antibody to HCV by using a microsphere-based immunoassay and flow cytometry.

T M McHugh1, M K Viele, E S Chase, D J Recktenwald.   

Abstract

Antibody to HCV core and NS3 was quantified by using a microsphere immunoassay and flow cytometry. Antibody to core and NS3 was elevated in the 85 seropositive blood donors tested. The amount of either antibody varied over two logs although greater variation was seen with the antibody to NS3 than was seen with antibody to core. In three documented acute HCV cases, the microsphere assay detected antibody prior to antibody detection using the reference methods. Twenty donor samples were indeterminate by the reference methods: 45% of these were indeterminate with the microsphere assay while 25% were negative and 30% were positive. As compared to enzyme immunoassay the microsphere assay showed a 5-fold increase in sensitivity. The microsphere assay demonstrated increased sensitivity for the quantification of specific antibody to HCV core and NS3 and was useful in resolving a significant proportion of indeterminate samples.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332816

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  3 in total

1.  Flow cytometric microsphere-based immunoassay: analysis of secreted cytokines in whole-blood samples from asthmatics.

Authors:  C Camilla; L Mély; A Magnan; B Casano; S Prato; S Debono; F Montero; J P Defoort; M Martin; V Fert
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 2.  Applications of flow cytometry to clinical microbiology.

Authors:  A Alvarez-Barrientos; J Arroyo; R Cantón; C Nombela; M Sánchez-Pérez
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

3.  Holographic molecular binding assays.

Authors:  Yvonne Zagzag; M Francesca Soddu; Andrew D Hollingsworth; David G Grier
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.